The APRI chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the APRI chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The APRI stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View APRI Detailed Price Forecast - CNN Money||View APRI Detailed Summary - Google Finance|
|View APRI Detailed Summary - Yahoo! Finance||View APRI Stock Research & Analysis - Zacks.com|
|View APRI Trends & Analysis - Trade-Ideas||View APRI Major Holders - Barrons|
|View APRI Call Transcripts - NASDAQ||View APRI Breaking News & Analysis - Seeking Alpha|
|View APRI Annual Report - CompanySpotlight.com||View APRI OTC Short Report - OTCShortReport.com|
|View APRI Fundamentals - TradeKing||View APRI SEC Filings - Bar Chart|
|View Historical Prices for APRI - The WSJ||View Performance/Total Return for APRI - Morningstar|
|View the Analyst Estimates for APRI - MarketWatch||View the Earnings History for APRI - CNBC|
|View the APRI Earnings - StockMarketWatch||View APRI Buy or Sell Recommendations - MacroAxis|
|View the APRI Bullish Patterns - American Bulls||View APRI Short Pain Metrics - ShortPainBot.com|
|View APRI Stock Mentions - StockTwits||View APRI Stock Mentions - PennyStockTweets|
|View APRI Stock Mentions - Twitter||View APRI Investment Forum News - Investor Hub|
|View APRI Stock Mentions - Yahoo! Message Board||View APRI Stock Mentions - Seeking Alpha|
|View Insider Transactions for APRI - SECform4.com||View Insider Transactions for APRI - Insider Cow|
|View APRI Major Holdings Summary - CNBC||View Insider Disclosure for APRI - OTC Markets|
|View Insider Transactions for APRI - Yahoo! Finance||View Institutional Holdings for APRI - NASDAQ|
|View APRI Stock Insight & Charts - FinViz.com||View APRI Investment Charts - StockCharts.com|
|View APRI Stock Overview & Charts - BarChart||View APRI User Generated Charts - Trading View|
Seelos Therapeutics, Inc. Announces Successful Completion of its Merger with Apricus Biosciences, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System (CNS) Disorders
Posted on Thursday January 24, 2019
Seelos Therapeutics, Inc. (Nasdaq:SEEL), a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders, announced today the completion of its previously disclosed merger with Apricus Biosciences, Inc. The combined company changed its name to Seelos Therapeutics, Inc. and will focus on the development and commercialization of CNS therapeutics with known mechanisms of action in areas with a highly unmet medical need. Seelos is expected to begin trading today, January 24, 2019, on The Nasdaq Capital Market under the ticker symbol “SEEL”. The previous ticker symbol was “APRI” (APRI). Seelos will maintain its headquarters in New York, New York and will be led by Chairman and Chief Executive Officer, Raj Mehra, Ph.D.
Apricus Biosciences Stockholders Approve Proposed Merger with Seelos Therapeutics, Inc.
Posted on Tuesday January 15, 2019
Apricus Biosciences, Inc. (APRI) has today reported that it obtained stockholder approval as required pursuant to the terms of the merger agreement with Seelos Therapeutics, Inc. and the related securities purchase agreement with selected investors or necessary under Nevada law, in order to complete the merger, the financing and related matters. The Company announced that over 95% of the votes cast were in favor of the merger with Seelos, over 85% of the votes cast were in favor of the reverse stock split and over 75% of the votes cast were in favor of each other proposal. “We are pleased that our responding stockholders indicated their support of the merger with Seelos by an overwhelming majority,” stated Richard W. Pascoe, Chief Executive Officer.
Apricus Biosciences Adjourns Special Meeting of Stockholders to New Date
Posted on Friday December 14, 2018
The Company announced that it needs additional time to solicit stockholder votes in order to obtain affirmative votes from a majority of the voting power of the Company’s outstanding common stock, which is required for certain proposals at the meeting: the reverse stock split (Proposal 2), which must be approved by a majority of the outstanding shares in order for the merger to close, and the name change to Seelos Therapeutics, Inc. (Proposal 3). The Company announced that over 90% of the votes cast to date have been in favor of the merger with Seelos (Proposal 1) and over 80% of the votes cast to date have been in favor of each other proposal. The special meeting was adjourned until 8:00 a.m., Pacific Time, on January 4, 2019 at Latham & Watkins LLP, located at 12670 High Bluff Drive, San Diego, California 92130, its original location.
Apricus Biosciences Reminds Shareholders to Vote Before the Special Meeting on December 14, 2018
Posted on Monday December 10, 2018
Apricus Biosciences, Inc. (APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, reminds shareholders to vote by proxy before the upcoming special stockholders meeting on December 14, 2018. Apricus is holding a special meeting of stockholders in order to obtain the stockholder approvals required pursuant to the terms of the Merger Agreement with Seelos Therapeutics, Inc. and the Securities Purchase Agreement to finance the post-merger corporation or necessary under Nevada law, in order to complete the merger, the financing and related matters. The Apricus special meeting will be held at 8:00 a.m., Pacific time, on December 14, 2018 at Latham & Watkins LLP, located at 12670 High Bluff Drive, San Diego, California 92130, unless postponed or adjourned to a later date. If you have questions or need help voting your shares, please call our proxy solicitation firm, Morrow Sodali LLC at 1-877-787-9239.